Mazdutide vs Survodutide
Mazdutide (Dual GLP-1/glucagon receptor agonist) and Survodutide (Dual GLP-1/glucagon receptor agonist) are documented as co-studied in the PeptiDex library. This page puts the two entries side by side on class, molecular weight, half-life, origin, mechanism and studied research areas — every value taken from the entry it belongs to.
Why these two are co-studied
Cross-referenced for research context — not a usage or combination recommendation.
At a glance
| Attribute | Mazdutide | Survodutide |
|---|---|---|
| Compound class | Dual GLP-1/glucagon receptor agonist | Dual GLP-1/glucagon receptor agonist |
| Research category | GLP-1 Family | GLP-1 Family |
| Length (amino acids) | Not documented | Not documented |
| Molecular weight | Not documented | Not documented |
| Half-life | Not documented | ~6-7 days (~120-170 hours) |
| Origin | An investigational dual agonist targeting the GLP-1 and glucagon receptors, developed by Eli Lilly and licensed to Innovent Biologics for the Chinese market (also known as IBI362 or LY3305677). It has been evaluated in clinical trials in the 2020s. | An investigational dual agonist of the GLP-1 and glucagon receptors developed by Boehringer Ingelheim (also known as BI 456906). It has been evaluated in clinical trials in the 2020s. |
“Not documented” means the PeptiDex entry records no value for that field. Nothing on this page is estimated, and no figure is carried over from one compound to the other.
How Mazdutide works
Mazdutide is a synthetic peptide agonist that activates both the GLP-1 and glucagon receptors, structurally based on the glucagon/oxyntomodulin family. GLP-1 agonism enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite, while glucagon-receptor agonism is proposed to increase energy expenditure and influence hepatic lipid metabolism. The combined activity is being studied for effects on body weight and metabolic parameters.
How Survodutide works
Survodutide is a synthetic peptide agonist that activates both the GLP-1 and glucagon receptors. GLP-1 agonism enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite, while glucagon-receptor agonism is proposed to raise energy expenditure and modulate hepatic metabolism. The combined action is being studied for effects on body weight and liver-related metabolic endpoints.
Mechanistic descriptions reflect published research-literature understanding and are quoted from each compound's own entry. Much peptide research is preclinical (in-vitro or animal-model); mechanism in humans may differ and is not established for many compounds.
Where each one appears in the literature
The research contexts each entry documents. Listing a research area is not a claim of efficacy or a therapeutic indication, and the two lists are not scored against each other.
Described in identical terms for both
Mazdutide
Survodutide
What sets each apart
Mazdutide
Mazdutide differs from tirzepatide by pairing GLP-1 with glucagon-receptor agonism (rather than GIP), and from single GLP-1 agonists by its dual-receptor action.
Survodutide
Survodutide is a GLP-1/glucagon dual agonist (like mazdutide) rather than a GIP/GLP-1 agonist like tirzepatide, and has been notably studied for liver disease endpoints.
Frequently asked questions
What is mazdutide and what receptors does it target?
Mazdutide (IBI362 / LY3305677) is a once-weekly dual agonist based on a mammalian oxyntomodulin analogue that activates both the GLP-1 and glucagon receptors. The glucagon-receptor arm — associated in research with increased energy expenditure and hepatic fat effects — distinguishes it from GLP-1 mono-agonists. It is studied in obesity and metabolic models, with much of the clinical work conducted in Chinese populations.
How is mazdutide dose-escalated in the research literature?
Reported protocols escalate weekly — for example a 9 mg cohort using 3 mg (weeks 1-4), 6 mg (weeks 5-8), then 9 mg (weeks 9-12), and a 10 mg cohort stepping 2.5 -> 5 -> 7.5 -> 10 mg over 16 weeks. Phase 3 (GLORY-1) work centered on 4 mg and 6 mg weekly maintenance doses. These are reference figures for research context only, not human dosing guidance.
How does mazdutide differ from tirzepatide?
Both are dual agonists, but mazdutide pairs GLP-1 with glucagon-receptor activity, whereas tirzepatide pairs GLP-1 with GIP-receptor activity. The glucagon arm is the mechanistic feature researchers study for its effects on energy expenditure and hepatic fat. Mazdutide is earlier in development and less broadly characterized.
What is survodutide and what receptors does it target?
Survodutide (BI 456906) is a dual glucagon-receptor / GLP-1-receptor agonist developed by Boehringer Ingelheim under license from Zealand Pharma. It is an acylated peptide carrying a C18 fatty-acid chain for half-life extension. In research the GLP-1 arm is associated with satiety and glucose effects while the glucagon arm is associated with energy expenditure and hepatic fat, and it is studied in obesity and MASH models.
What is survodutide's half-life and what does it imply for study design?
Survodutide has a reported half-life on the order of ~6-7 days (roughly 120-170 hours across sources), supporting once-weekly administration. Steady state is generally reached by about week 5 of weekly dosing, so protocols include a multi-week escalation before maintenance readouts. The long half-life also means a multi-week washout after discontinuation.
How is survodutide dose-escalated in the clinical literature?
A phase 2 obesity dose-finding trial studied once-weekly doses of 0.6, 2.4, 3.6, and 4.8 mg, using an approximately 20-week dose-escalation phase followed by a maintenance phase. Escalation is used to manage gastrointestinal tolerability. These are reference figures for research context only, not human dosing guidance.
Answers are the ones published on each compound's own PeptiDex entry. They are educational summaries of research-literature context and are not medical advice.